Biodexa Pharmaceuticals
BDRX
8 hedge funds and large institutions have $48.1K invested in Biodexa Pharmaceuticals in 2026 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, 4 reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
14% more funds holding
Funds holding: 7 → 8 (+1)
0.68% less ownership
Funds ownership: 2.9% → 2.22% (-0.68%)
79% less capital invested
Capital invested by funds: $228K → $48.1K (-$180K)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CIAM
Caitong International Asset Management
Hong Kong
|
+$17 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$159K |
| 2 |
AC
Armistice Capital
New York
|
-$15.8K |
| 3 |
GI
GAMMA Investing
Foster City,
California
|
-$5.24K |
| 4 |
RhumbLine Advisers
Boston,
Massachusetts
|
-$3 |
| 5 |
SS
SBI Securities
Tokyo,
Japan
|
-$3 |
BDRX Hedge Fund Activity: Q2 2026 in Review
8 of the 8,303 institutional investors tracked by Wall St. Rank reported a position in Biodexa Pharmaceuticals (BDRX) for Q2 2026, worth a combined $48.1K — down 79% from $228K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new BDRX positions and 1 closed out — a net gain of 1 holder — while 0 added to existing stakes and 4 trimmed.
The largest buyer was Caitong International Asset Management, opening a new position worth an estimated $17. The largest seller was Sabby Management, exiting entirely with an estimated $159K sold.
- 8 institutional investors held Biodexa Pharmaceuticals (BDRX) as of Q2 2026, up from 7 in Q1 2026.
- Funds reported $48.1K of Biodexa Pharmaceuticals stock for Q2 2026, down 79% quarter-over-quarter.
- 2 funds opened new Biodexa Pharmaceuticals positions in Q2 2026 and 1 closed out, a net change of +1 holder.
- The largest Biodexa Pharmaceuticals buyer in Q2 2026 was Caitong International Asset Management, an estimated $17 added.
- The largest Biodexa Pharmaceuticals seller in Q2 2026 was Sabby Management, an estimated $159K sold.
Based on aggregated 13F filings for Q2 2026.